- Conditions
- Spinal Muscular Atrophy
- Interventions
- Nusinersen
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 2 Years to 15 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Dallas, Texas + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–32
of 32
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Muscular Atrophy, Spinal
- Interventions
- Nusinersen
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 7
- States / cities
- Sacramento, California • Aurora, Colorado • Chicago, Illinois + 4 more
- Conditions
- Muscular Atrophy, Spinal
- Interventions
- Nusinersen, ThecaFlex DRx System
- Drug · Device
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Orange, California • Palo Alto, California + 9 more
- Conditions
- Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA, Neuromuscular Diseases, Muscular Atrophy, Atrophy, Muscular Atrophy, Spinal, Neuromuscular Manifestations, Anti-myostatin
- Interventions
- Apitegromab, Placebo
- Drug
- Lead sponsor
- Scholar Rock, Inc.
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 23 more
- Conditions
- Spinal Muscular Atrophy
- Interventions
- nusinersen
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 2 Years to 14 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Dallas, Texas + 1 more
- Conditions
- Spinal Muscular Atrophy
- Interventions
- nusinersen
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 21 Days to 210 Days
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 3
- States / cities
- Stanford, California • Orlando, Florida • New York, New York
- Conditions
- Spinal Muscular Atrophy
- Interventions
- Not listed
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 5 Years to 20 Years
- Enrollment
- 24 participants
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3, Neuromuscular Manifestations, Anti-myostatin
- Interventions
- Apitegromab, Nusinersen, Risdiplam
- Drug
- Lead sponsor
- Scholar Rock, Inc.
- Industry
- Eligibility
- Up to 2 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Orange, California • Palo Alto, California + 9 more